According to Open Orphan, the study is expected to begin at hVIVO’s quarantine clinic in East London the second half of 2021. The company then expects the study to be fully completed by the end of 2021 and generate £2.5m of revenue.
hVIVO’s challenge studies require healthy volunteers to take part, with its facility offering specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral and vaccine discovery and development.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).